Lipo-dox and Cyclophosphamide /5-Fluorouracil in Patients With Metastatic Breast Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To determine the overall objective response rate of pegylated liposomal doxorubicin
（Lipo-Dox）combined with cyclophosphamide/5-FU as second-line treatment in patients with
metastatic breast cancer.